MedTrace Logo

Interventional Validation of an MDS-Specific Measure of Quality of Life: Assessing the Responsiveness of the Quality of Life in Myelodysplasia Scale (QUALMS-1) to Different Hypomethylating Agent Regimens for Low and Intermediate Risk Disease

NCT02378701 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 102

Last updated 2022-07-29

No results posted yet for this study

Summary

The goal of this research study is to test a quality-of-life questionnaire called QUALMS-1 in patients with MDS.

This is an investigational study.

Up to 240 participants will be enrolled in this multicenter study. Up to 175 will take part at MD Anderson.

Conditions

Interventions

BEHAVIORAL

QUALMS-1 Questionnaire

Participants complete the QUALMS-1 during first treatment visit, and after 4th cycle of treatment or when treatment stops.

BEHAVIORAL

FACT-An Questionnaire

Participants complete the FACT-An during first treatment visit, and after 4th cycle of treatment or when treatment stops.

Sponsors & Collaborators

  • MDS Clinical Research Consortium

    collaborator UNKNOWN

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Guillermo Garcia-Manero, MD · M.D. Anderson Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2022-07-18
Completion
2022-07-18

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02378701 on ClinicalTrials.gov